GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » MedMira Inc (OTCPK:MMIRF) » Definitions » EBITDA Margin %

MedMira (MedMira) EBITDA Margin % : -209.01% (As of Jan. 2024)


View and export this data going back to . Start your Free Trial

What is MedMira EBITDA Margin %?

EBITDA Margin % is calculated as EBITDA divided by its Revenue. MedMira's EBITDA for the three months ended in Jan. 2024 was $-0.23 Mil. MedMira's Revenue for the three months ended in Jan. 2024 was $0.11 Mil. Therefore, MedMira's EBITDA margin for the quarter that ended in Jan. 2024 was -209.01%.


MedMira EBITDA Margin % Historical Data

The historical data trend for MedMira's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

MedMira EBITDA Margin % Chart

MedMira Annual Data
Trend Jul14 Jul15 Jul16 Jul17 Jul18 Jul19 Jul20 Jul21 Jul22 Jul23
EBITDA Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -242.29 -122.61 8.65 -112.09 -364.02

MedMira Quarterly Data
Apr19 Jul19 Oct19 Jan20 Apr20 Jul20 Oct20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24
EBITDA Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -185.83 -387.34 -1,173.08 -459.30 -209.01

Competitive Comparison of MedMira's EBITDA Margin %

For the Biotechnology subindustry, MedMira's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


MedMira's EBITDA Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, MedMira's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where MedMira's EBITDA Margin % falls into.



MedMira EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

MedMira's EBITDA Margin % for the fiscal year that ended in Jul. 2023 is calculated as

EBITDA Margin %=EBITDA (A: Jul. 2023 )/Revenue (A: Jul. 2023 )
=-1.194/0.328
=-364.02 %

MedMira's EBITDA Margin % for the quarter that ended in Jan. 2024 is calculated as

EBITDA Margin %=EBITDA (Q: Jan. 2024 )/Revenue (Q: Jan. 2024 )
=-0.232/0.111
=-209.01 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


MedMira  (OTCPK:MMIRF) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.


MedMira EBITDA Margin % Related Terms

Thank you for viewing the detailed overview of MedMira's EBITDA Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


MedMira (MedMira) Business Description

Traded in Other Exchanges
Address
155 Chain Lake Drive, Suite 1, Halifax, NS, CAN, B3S 1B3
MedMira Inc is a biotechnology company that is engaged in the business of research, development, and manufacturing of rapid diagnostics and technologies. The company has one reportable operating segment, rapid diagnostic products and services. The product line of the company includes RevealHIV which detects antibodies to HIV-1 and HIV-2 in whole blood, serum or plasma; H Pylori which detects antibodies in serum, plasma, and whole blood; syphilis which detects treponema pallidum antibodies in serum, plasma, and whole blood; among other products. The company generates revenue geographically from North America, Europe, Asia pacific. The majority of the revenue is generated from North America.

MedMira (MedMira) Headlines

From GuruFocus

Management Cease Trade Order Update

By GlobeNewswire GlobeNewswire 12-26-2018

MedMira Reports Second Quarter Results

By GlobeNewswire GlobeNewswire 03-30-2018

Progress Update on Securities

By ACCESSWIRE 08-31-2023

MedMira receives CE mark for its VYRA(TM) CoV2Flu Antigen Test

By ACCESSWIRE ACCESSWIRE 01-11-2023

MedMira Reports Third Quarter Results FY2023

By ACCESSWIRE 06-30-2023

MedMira Introduces VYRA TriDemic

By ACCESSWIRE ACCESSWIRE 12-30-2022

MedMira Receives CE Mark for Its VYRA(TM) COVID-19 Antigen Test

By ACCESSWIRE ACCESSWIRE 10-14-2022

MedMira Reports Third Quarter Results

By GlobeNewswire GlobeNewswire 06-30-2018